CIK 0001585608
- Non-accelerated filer
- Smaller reporting company
Jaguar Health, Inc.
Sign in to watch- Ticker
- JAGX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- Phone
- +1 415-371-8300
- Business address
- 200 PINE STREET SUITE 400, SAN FRANCISCO, CA, 94104
- Former names
- Jaguar Animal Health, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 83 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-05-17 | King Steven R. See Remarks | Option exercise · Restricted stock units | −1 | 0 | ||
| 2025-05-17 | CONTE LISA A CEO and President | Option exercise | +2 | 666 | ||
| 2025-05-17 | CONTE LISA A CEO and President | Option exercise · Restricted stock units | −2 | 0 | ||
| 2025-03-31 | MICEK JOHN Director | Purchase · Convertible Promissory Note | +9,000 | $50,000.00 | $450.0M | 9,000 |
| 2025-03-31 | MICEK JOHN Director | Purchase · Warrant to Purchase Common Stock | +9,000 | 9,000 | ||
| 2025-03-31 | King Steven R. See Remarks | Purchase · Convertible Promissory Note | +3,600 | $20,000.00 | $72.0M | 3,600 |
| 2025-03-31 | King Steven R. See Remarks | Purchase · Warrant to Purchase Common Stock | +3,600 | 3,600 | ||
| 2025-03-31 | Siegel Jonathan B. Director | Purchase · Convertible Promissory Note | +9,000 | $50,000.00 | $450.0M | 9,000 |
| 2025-03-31 | Siegel Jonathan B. Director | Purchase · Warrant to Purchase Common Stock | +9,000 | 9,000 | ||
| 2025-03-31 | CONTE LISA A CEO and President | Purchase · Convertible Promissory Note | +9,000 | $50,000.00 | $450.0M | 9,000 |
| 2025-03-31 | CONTE LISA A CEO and President | Purchase · Warrant to Purchase Common Stock | +9,000 | 9,000 | ||
| 2025-03-31 | Chaturvedi Pravin R Chief Scientific Officer | Purchase · Convertible Promissory Note | +3,600 | $20,000.00 | $72.0M | 3,600 |
| 2025-03-31 | Chaturvedi Pravin R Chief Scientific Officer | Purchase · Warrant to Purchase Common Stock | +3,600 | 3,600 | ||
| 2025-03-31 | BOCHNOWSKI JAMES J Director | Purchase · Convertible Promissory Note | +27,002 | $150,000.00 | $4.1B | 27,002 |
| 2025-03-31 | BOCHNOWSKI JAMES J Director | Purchase · Warrant to Purchase Common Stock | +27,002 | 27,002 | ||
| 2025-03-31 | Wolin Jonathan S. See Remarks | Purchase · Convertible Promissory Note | +9,000 | $50,000.00 | $450.0M | 9,000 |
| 2025-03-31 | Wolin Jonathan S. See Remarks | Purchase · Warrant to Purchase Common Stock | +9,000 | 9,000 | ||
| 2025-03-31 | Lizak Carol R. Chief Financial Officer | Purchase · Convertible Promissory Note | +5,400 | $30,000.00 | $162.0M | 5,400 |
| 2025-03-31 | Lizak Carol R. Chief Financial Officer | Purchase · Warrant to Purchase Common Stock | +5,400 | 5,400 | ||
| 2024-10-08 | Lizak Carol R. Chief Financial Officer | Grant or award | +4,280 | 4,297 |
Page 3 of 10 · 185 trades